Leeuwenberg J F, Dentener M A, Buurman W A
Department of Surgery, University of Limburg, Maastricht, The Netherlands.
J Immunol. 1994 May 15;152(10):5070-6.
Previously we demonstrated that two soluble(s) tumor necrosis factor receptors, TNF-R55 as well as sTNF-R75, are constitutively released in vitro by monocytes, and that this release was markedly enhanced after activation. Because LPS is an important activator of monocytes, we investigated the effect of LPS on sTNF-R release by monocytes. It was found that release of sTNF-R75, but not (or minimally) release of sTNF-R55, was enhanced after activation with LPS, reaching plateau levels after approximately 2 days. CD14, one of the membrane receptors for LPS, is an intermediate in this process, as shown in experiments using mAb directed against CD14. Under serum-free conditions, LPS-induced sTNF-R75 release was less as compared with release in the presence of serum, suggesting involvement of serum proteins. Addition of LPS binding protein (LBP) enhanced the LPS-induced sTNF-R75 release under serum-free conditions, but had no effect in the presence of serum. On the other hand, bactericidal/permeability-increasing protein (BPI), known to possess LPS neutralizing activity, inhibited LPS-induced sTNF-R75 release. Furthermore, cell surface expression of both types of TNF-R was shown to be controlled by LPS, LBP, and BPI. LPS caused, within 1 h, a complete reduction of TNF-R55 as well as TNF-R75 expression, followed by enhanced re-expression of both receptors after 24 h. The down-modulation of expression was increased by LBP, whereas BPI counteracted the LPS-induced down-regulation. The LPS-enhanced release of sTNF-R75, capable of inactivation of TNF, as well as LPS-induced initial down-modulation of TNF-R expression leading to postulated temporary unresponsiveness to TNF may share in a physiological mechanism to carefully control the effects of TNF.
先前我们证明,两种可溶性肿瘤坏死因子受体,即TNF-R55和sTNF-R75,在体外由单核细胞组成性释放,并且这种释放在激活后显著增强。由于脂多糖(LPS)是单核细胞的重要激活剂,我们研究了LPS对单核细胞释放sTNF-R的影响。结果发现,用LPS激活后,sTNF-R75的释放增强,而sTNF-R55的释放未增强(或仅轻微增强),大约2天后达到平台水平。LPS的膜受体之一CD14是这一过程的中间介质,这在使用针对CD14的单克隆抗体的实验中得到了证实。在无血清条件下,与有血清存在时的释放相比,LPS诱导的sTNF-R75释放较少,提示血清蛋白参与其中。添加LPS结合蛋白(LBP)可增强无血清条件下LPS诱导的sTNF-R75释放,但在有血清存在时无作用。另一方面,已知具有LPS中和活性的杀菌/通透性增加蛋白(BPI)可抑制LPS诱导的sTNF-R75释放。此外,两种类型的TNF-R的细胞表面表达均显示受LPS、LBP和BPI的调控。LPS在1小时内导致TNF-R55以及TNF-R75表达完全降低,随后在24小时后两种受体的重新表达增强。LBP增加了表达的下调,而BPI则抵消了LPS诱导的下调。能够使TNF失活的sTNF-R75的LPS增强释放,以及LPS诱导的TNF-R表达的初始下调导致推测的对TNF的暂时无反应性,可能共同参与了一种生理机制,以谨慎控制TNF的作用。